Boston Medicaid Cuts End GLP-1 Weight-Loss Coverage for Low-Income Patients This Month
Updated
Updated · The Washington Post · Jul 25
Boston Medicaid Cuts End GLP-1 Weight-Loss Coverage for Low-Income Patients This Month
3 articles · Updated · The Washington Post · Jul 25
Summary
Boston primary care doctors say low-income patients have lost access to Ozempic and other GLP-1 drugs after Massachusetts Medicaid stopped covering them for weight loss this month.
That cutoff is forcing physicians to shift from prescribing the drugs to counseling patients on diet, exercise and other ways to manage obesity without medications many can no longer afford.
The change sharpens a divide in obesity treatment, leaving patients with means able to keep using high-demand GLP-1 medicines while poorer patients are pushed out.
In Boston, the loss of coverage underscores how state Medicaid decisions can determine whether newer obesity drugs remain a medical option or become financially out of reach.
As 40 million Americans embrace weight-loss drugs, what happens to the thousands suddenly forced into withdrawal by abrupt insurance cancellations?
Could emerging oral weight-loss pills finally shatter the massive wealth gap in obesity treatment before vulnerable patients suffer irreversible health setbacks?